Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maternal determinants of infant immunity to pertussis (MADI-02)
2024-517893-73-00Phase 4Completed
- Sponsor
- Université libre de Bruxelles
- Start
- Oct 2024
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of diphtheria, tetanus, and acellular pertussis vaccine and DTaP-IPV-Hep B-PRP-T vaccine in pertussis (2 arms), sponsored by Université libre de Bruxelles. Primary endpoint: Magnitude of pertussis antibody responses. Started Oct 2024; status: completed.
02
Drugs
diphtheria, tetanus, and acellular pertussis vaccineDTaP-IPV-Hep B-PRP-T vaccine
03
Conditions
pertussis
Beyond the preview
Go deeper on 2024-517893-73-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517893-73-00.